Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd
CN
News trends
Position:
Homepage
/
/
/
Dongfang Baitai won the top 100 "coolest black technology" in China in 2016
Check category

Dongfang Baitai won the top 100 "coolest black technology" in China in 2016

  • Categories:Company News
  • Author:
  • Origin:Dongfang Baitai
  • Time of issue:2022-05-20
  • Views:538

(Summary description)On November 11, 2016, the grand ceremony of "T100 New Technology and New Product Innovation Action" was held in Beijing National Convention Center. The "Top 100 Black Science and Technology Companies in China" were unveiled on the spot. Beijing Dongfang Baitai Biotechnology Co., Ltd. won the honor by virtue of its major new drug with independent intellectual property rights, Exendin-4 immune fusion protein, a long-acting drug for diabetes.

Dongfang Baitai won the top 100 "coolest black technology" in China in 2016

(Summary description)On November 11, 2016, the grand ceremony of "T100 New Technology and New Product Innovation Action" was held in Beijing National Convention Center. The "Top 100 Black Science and Technology Companies in China" were unveiled on the spot. Beijing Dongfang Baitai Biotechnology Co., Ltd. won the honor by virtue of its major new drug with independent intellectual property rights, Exendin-4 immune fusion protein, a long-acting drug for diabetes.

  • Categories:Company News
  • Author:
  • Origin:Dongfang Baitai
  • Time of issue:2022-05-20
  • Views:538
Information

On November 11, 2016, the grand ceremony of "T100 New Technology and New Product Innovation Action" was held in Beijing National Convention Center. The "Top 100 Black Science and Technology Companies in China" were unveiled on the spot. Beijing Dongfang Baitai Biotechnology Co., Ltd. won the honor by virtue of its major new drug with independent intellectual property rights, Exendin-4 immune fusion protein, a long-acting drug for diabetes.

 

Awarding site of "T100 New Technology and New Product Innovation Action"

 

2016 "T100 New Technology and New Product Innovation Action" was jointly sponsored by Beijing Science and Technology Cooperation Center and China Private Science and Technology Promotion Association under the leadership of the Ministry of Science and Technology. It aims to check the direction of future scientific and technological development, and show and introduce new technologies and new product achievements. It supports the innovation of new technologies and products of all parties, gives play to the leading role of Beijing National Science and Technology Innovation Center, and emphasizes that innovation is the first driving force for development.

This activity selected the "Top 100 New Technology and New Products" in 2016 from the representative new technology and new products in 10 major fields including medical and health, thousands of manufacturers and scientific research institutions.

 

Dongfang Baitai won the medal of "T100 New Technology and New Product Innovation Action"

 

Ji Xiaobing, member of the Party Leadership Group of Beijing Municipal Science and Technology Commission and director of Beijing Science and Technology Cooperation Center, Zhou Xiaobai, deputy director of Beijing Science and Technology Cooperation Center, Ma Yanmin, executive vice president of China Association for the Promotion of Private Science and Technology, Wang Jinyong, director of the High tech Division of Beijing Municipal Science and Technology Commission, and other leaders attended the event. A total of 427 representatives from enterprises, investment institutions and the media attended the launch ceremony.

 

Leaders of the Science and Technology Cooperation Center presented awards to Manager Zhang Liping (third from the left), the representative of Dongfang Baitai

 

Dongfang Baitai is a high-end innovative enterprise in the medical and health field. It has a complete set of key technologies, equipment, platforms and systems for antibody research and development. And a senior technology research and development team of more than 100 people has been established. It truly realizes the penetration of antibody R&D technology and the whole production process. Dongfang Baitai has always been focusing on the research, development and production of new products for major disease treatment and preventive biological medicine. More than 20 R&D pipeline layouts have been carried out in anti-tumor, diabetes, autoimmune diseases and other major diseases. It will make outstanding contributions to the prevention and treatment of major diseases in China, as well as the promotion of China's biological medicine innovation ability and rapid development of industrialization.

 

 

Dongfang Baitai R&D platform

 

The award-winning JY09 Exendin-4 immune fusion protein is a long-term drug for the treatment of diabetes (only once a week). It also has the function of repairing islets of langerhans. It promotes insulin secretion. Compared with the existing conventional drug insulin, it has incomparable advantages. By coupling the Fc fragment of human IgG2 with Exendin-4 through a special connecting peptide, the original biological activity is maintained while prolonging the half-life of Exendin-4 in vivo, while the production cost is greatly reduced and the therapeutic effect is improved.

The Exendin-4 immune fusion protein project is a research and development team composed of nearly 100 high-level technical talents of Dongfang Baitai, which has independently developed a new class I biological drug for the treatment of type II diabetes after seven years. At present, Phase I clinical study is under way. It is expected to obtain a new drug certificate in 2021. It is a "triple" project supported by the State for major new drug discovery. It is a special project supported and promoted by Beijing Municipal Science and Technology Commission. It is also a strategic emerging industry proposed by the Twelfth Five Year Plan. It has obtained domestic and foreign invention patent authorization from China, the United States, the European Union, Japan, South Korea, Eurasia, Brazil and India.

This "China's Top 100 Black Science and Technology" award is another major award after Exendin-4 immune fusion protein won the gold medal of Beijing Innovation and Invention Competition in May 2016. In the 10th Beijing Invention and Innovation Competition, Dongfang Baitai's Exendin-4 immune fusion protein project, a long-acting drug for diabetes, stood out from more than 1800 projects in the competition for its outstanding innovation, and won the gold medal of the competition at one fell swoop.

 

Exendin-4 immune fusion protein won the gold medal of "Beijing Invention and Innovation Competition"

 

Dongfang Baitai will continue to strictly abide by the core values of "responsibility, quality, innovation and health". We are always committed to providing high-quality, safe and long-term innovative antibody drugs for patients, helping human beings extend their life cycle, improve their quality of life, and protect their healthy lives.

Scan the QR code to read on your phone

推荐新闻

Follow us

1

Follow the official WeChat official account

Or search "Oriental Baitai"

More exciting waiting for you!

Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com

Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd    SEO    京ICP备********号 

Beijing Dongfang Baitai Biotechnology Co., Ltd

Online customer service
Customer service hotline
010-51571019 010-51571019
Service time:
8:30 - 17:30
Customer service group:
在线客服